2-Oxo-PCE, which is also referred to as N-ethyldeschloroketamine, eticyclidone, and O-PCE, is a dissociative anesthetic belonging to the arylcyclohexylamine class. It shares a close structural resemblance with deschloroketamine and eticyclidine and has been available for purchase online as a designer drug.
|CAS Number||6740-82-5 hydrochloride: 4551-92-2|
|Chemical and physical data|
|Molar mass||217.312 g·mol−1|
1. What is 2-Oxo-PCE?
- 2-Oxo-PCE, also known as N-ethyldeschloroketamine, eticyclidone, and O-PCE, is a synthetic dissociative anesthetic. It is chemically related to deschloroketamine and eticyclidine and is considered a designer drug.
2. How is 2-Oxo-PCE typically used?
- 2-Oxo-PCE is commonly used for its dissociative effects and can be taken orally, inhaled, or insufflated (snorted). Users may choose their preferred method of administration.
3. What are the effects of 2-Oxo-PCE?
- The effects of 2-Oxo-PCE are similar to other dissociative substances, leading to altered perception, dissociation, and a sense of detachment from reality.
4. Is 2-Oxo-PCE legal?
- Legal status varies by country and jurisdiction. The legality of 2-Oxo-PCE is subject to change, so it’s essential to check the laws in your specific area.
5. Is 2-Oxo-PCE safe to use?
- The safety of using 2-Oxo-PCE is a matter of concern, as its long-term effects and potential risks are not well-documented. As with many designer drugs, there can be health risks associated with use, including unknown purity and possible adverse reactions.
6. What are the risks and side effects of using 2-Oxo-PCE?
- Common side effects may include nausea, disorientation, hallucinations, and impaired motor skills. Overdosing can lead to more severe symptoms such as anxiety, confusion, and potentially life-threatening conditions.
7. Can 2-Oxo-PCE be addictive?
- There is a potential for psychological dependence with repeated use, but it is not considered highly physically addictive like some other substances.
8. How can I reduce the risks associated with 2-Oxo-PCE use?
- If you choose to use 2-Oxo-PCE, it’s essential to start with a low dose, be in a safe environment, and have someone you trust present. Avoid mixing it with other substances and be aware of its potential adverse effects.
9. Is there a safe or recommended dosage for 2-Oxo-PCE?
- The dosage can vary based on an individual’s tolerance and experience. Starting with a low dose is advisable, and it’s essential to monitor how your body reacts before considering more.
10. Where can I find help or support for 2-Oxo-PCE-related issues?
- If you or someone you know is struggling with substance use or addiction, it’s crucial to seek professional help. Reach out to addiction treatment centers or healthcare providers for guidance and support.
11. Can 2-Oxo-PCE be used for any medical purposes?
- 2-Oxo-PCE is not approved for medical use and should not be considered a substitute for prescribed medications or treatments.
Please note that this information is for informational purposes only, and the use of designer drugs like 2-Oxo-PCE carries risks and legal implications. Always prioritize your health and safety and be aware of the laws in your area.
- The Controlled Drugs and Substances Act (S.C. 1996, c. 19) – SCHEDULE I is the relevant legal framework in Canada. For more information, you can visit the Government of Canada’s Justice Laws Website. (Retrieved on July 15, 2020)
- In April 2020, Cheng WC and Dao KL reported the emergence of Deschloro-N-ethyl-ketamine, an analog of ketamine, in drug seizures and drug driving cases in Hong Kong. Their findings are published in the Journal of Analytical Toxicology, Volume 44, Issue 8, pages 886–895. DOI: 10.1093/jat/bkaa038. PMID: 32364605.
- Swedish authorities took action to classify fourteen new substances as either narcotics or hazardous materials on November 12, 2018. This development was reported in the Swedish language publication “Fjorton nya ämnen klassas som narkotika eller hälsofarlig vara.”
- Detailed information about “deschloro-N-ethyl-Ketamine (hydrochloride)” can be found at www.caymanchem.com.
- Jason W. and Brandt SD contributed to the understanding of 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances, which is detailed in Handbook of Experimental Pharmacology, Volume 252, published by Springer International Publishing. The relevant section can be found on pages 305–352. DOI: 10.1007/164_2018_148. ISBN: 978-3-030-10561-7. PMID: 30196446.
- In December 2017, Chong YK, Tang MH, Chan CL, Li YK, Ching CK, and Mak TW discussed the presence of “2-oxo-PCE,” a ketamine analog, on the streets in an article published in the Hong Kong Medical Journal. DOI: 10.12809/hkmj177089. PMID: 29226843.
- A cluster of acute poisonings associated with an emerging ketamine analog, 2-oxo-PCE, was documented in an article by Tang MH, Chong YK, Chan CY, Ching CK, Lai CK, Li YK, and Mak TW, published in Forensic Science International in September 2018. The relevant research can be found in Volume 290, pages 238–243. DOI: 10.1016/j.forsciint.2018.07.014. PMID: 30081327. S2CID: 207558276.
- A clinical laboratory perspective on new psychoactive substance use in Hong Kong over a nine-year period was provided by Tang MH, Hung LY, Lai CK, Ching CK, and Mak TW. This information is available in the Hong Kong Journal of Emergency Medicine, Volume 26, Issue 3, on pages 179–185. DOI: 10.1177/1024907918798553. ISSN: 1024-9079.
- In April 2019, Li C, Lai CK, Tang MH, Chan CC, Chong YK, and Mak TW discussed the proliferation of ketamine analogs in Hong Kong. Their findings were published in the Hong Kong Medical Journal, Volume 25, Issue 2, on page 169. DOI: 10.12809/hkmj197863. PMID: 30971512.
- A fatal case involving N-Ethyldeschloroketamine (2-Oxo-PCE) and Venlafaxine is detailed in an article by Theofel N, Möller P, Vejmelka E, Kastner K, Roscher S, Scholtis S, and Tsokos M, published in the Journal of Analytical Toxicology in March 2019. This information can be found in Volume 43, Issue 2, pages e2–e6. DOI: 10.1093/jat/bky063. PMID: 30365028.
- Newly emerging drugs of abuse were discussed by Tamama K and Lynch MJ in October 2019. This information is available in the “Substance Use Disorders” section of the Handbook of Experimental Pharmacology, Volume 258, on pages 463–502. DOI: 10.1007/164_2019_260. ISBN: 978-3-030-33678-3. PMID: 31595417. S2CID: 203983418.